Your browser doesn't support javascript.
loading
The Use of Galactomannan Antigen Assays for the Diagnosis of Invasive Pulmonary Aspergillosis in the Hematological Patient: A Systematic Review and Meta-Analysis.
Bukkems, Lydia M P; van Dommelen, Laura; Regis, Marta; van den Heuvel, Edwin; Nieuwenhuizen, Laurens.
Afiliación
  • Bukkems LMP; Maxima Medical Centre, De Run 46000, 5504 DB Veldhoven, The Netherlands.
  • van Dommelen L; Ziekenhuis Gelderse Vallei, Willy Brandtlaan 10, 6716 RP Ede, The Netherlands.
  • Regis M; Mathematics and Computer Science, Eindhoven University of Technology, Building Helix, Postbus 513, 5600 MB Eindhoven, The Netherlands.
  • van den Heuvel E; Mathematics and Computer Science, Eindhoven University of Technology, Building Helix, Postbus 513, 5600 MB Eindhoven, The Netherlands.
  • Nieuwenhuizen L; Maxima Medical Centre, De Run 46000, 5504 DB Veldhoven, The Netherlands.
J Fungi (Basel) ; 9(6)2023 Jun 15.
Article en En | MEDLINE | ID: mdl-37367610
ABSTRACT
The optimal cut-off value of the optical density index of the galactomannan antigen assays (GM) for diagnosing invasive pulmonary aspergillosis in hematological patients is a disputed topic. This article conducts a systematic review with a meta-analysis to establish which optical density index (ODI) cut-off value should be implemented into clinical practice. Pubmed, Embase and Cochrane databases were searched (N = 27). The pooled data, using a generalized linear mixed model with binomial distribution, resulted in an overall serum sensitivity of 0.76 and a specificity of 0.92. For serum ODI 0.5 there was a pooled sensitivity of 0.92 and a specificity of 0.84. The pooled data of all broncho-alveolar lavage (BAL) studies resulted in an overall sensitivity of 0.80 and a specificity of 0.95. For BAL ODI 0.5, there was a pooled sensitivity of 0.75 and a specificity of 0.88. For the BAL ODI 1.0 pooling, the studies resulted in a sensitivity of 0.75 and a specificity of 0.96. Serum ODI of 0.5 and BAL ODI of 1.0 are the most suitable cut-offs for clinical practice. However, our study affirms that the evidence for the use of GM in clinical practice for the hematological malignancy patient is currently insufficient and more research is needed to determine the diagnostic value of GM.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Systematic_reviews Idioma: En Revista: J Fungi (Basel) Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Systematic_reviews Idioma: En Revista: J Fungi (Basel) Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos